跳至主要内容
临床试验/IRCT2013100714925N1
IRCT2013100714925N1已完成2 期

The effect of Familact probiotic supplementation on lipid profile, glycemic control and insulin levels in patients with type 2 diabetes

Vice chancellor of Shahid Beheshti Endocrinology Research center0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
25 years 至 65 years(—)
性别
All

入选标准

  • Having type 2 diabetes mellitus; the age range was 25 to 65 years with a fifteen-year maximal period of type 2 diabetes mellitus ; controlled glucose and lipid levels of the patients were considered ; taking drugs prescribed by doctors were permitted until their dosages were unchanged during the intervention. Exclusion criteria: Having replacement treatments like Hormone or supplemental vitamins ; tobacco and alcohol use ; clinical signs of chronic kidney, liver or pulmonary disease ; chronic or acute inflammatory disease (especially acute pancreatic inflammation and Endocarditis) ; heart valve disease ; short bowel syndrome ; allergies ; immunosuppressives ; pregnancy and lactation and taking less than 10% of probiotic or placebo supplements.

排除标准

  • 未提供

研究者

发起方
Vice chancellor of Shahid Beheshti Endocrinology Research center

相似试验